Jennifer A. E. Esteves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer A. E. Esteves has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aaron S. Meyer
Department of Bioengineering University of California Los Angeles CA 90095 USA
1 shared publication- Angela Carey
Department of Biomedical Engineering, Washington University in St Louis, 1 Brookings Dr, Saint Louis, Saint Louis, Missouri, 63130-4899, UNITED STATES
1 shared publication Anna Wirasaputra
Department of Chemical Engineering University of Massachusetts Amherst MA 01002 USA
1 shared publicationAritra Nath Kundu
Department of Chemical Engineering University of Massachusetts Amherst MA 01002 USA
1 shared publicationFarnaz Mohammadi
Department of Bioengineering University of California Los Angeles CA 90095 USA
1 shared publication- Huanzhu Jiang
Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by IOP Publishing in Biofabrication
- Vol. 17 (4) , 045023
Engineered heart tissues formed with cardiac progenitors and differentiated cardiomyocytes exhibit similar physiologic properties at differentiation-matched timepoints
Congenital heart diseases, including single ventricle heart defects such as hypoplastic left and right heart syndromes, remain a leading cause of neonatal death and long-term morbidity. Regenerative medicine approaches hold great therapeutic promise for treating single ventricle disease, specifically through the use of human pluripotent stem cell-derived cardiomyocytes (iPSC-CM) to generate pulsatile conduits capable of growing and developing over time within the recipient. However, current strategies for rapidly fabricating large-scale engineered heart muscle to create such conduits face limitations, including the shear stress generated during most bioprinting processes along with harsh enzymatic treatments required for initial singularization of cells prior to bioprinting, which together can compromise cell viability and downstream tissue function. Here, we explored the use of derived cardiovascular progenitors (iPSC-CVP) as an alternative to fully differentiated cardiomyocytes as a potential cell source for future biomanufacturing efforts. We demonstrate that iPSC-CVP can be used to form functional engineered heart tissues with similar electrophysiological properties to tissues formed from fully differentiated iPSC-CM, while also being more amenable to enzymatic dissociation and mechanical manipulation. Our results suggest that iPSC-CVP may be an ideal cell population for future efforts in biofabrication of contractile structures such as engineered heart muscle and pulsatile conduits.
- 1 October 2025
- Published by IOP Publishing in Biofabrication
- Vol. 17 (4) , 045023
Open AccessEngineered heart tissues formed with cardiac progenitors and differentiated cardiomyocytes exhibit similar physiologic properties at differentiation-matched timepoints
Congenital heart diseases, including single ventricle heart defects such as hypoplastic left and right heart syndromes, remain a leading cause of neonatal death and long-term morbidity. Regenerative medicine approaches hold great therapeutic promise for treating single ventricle disease, specifically through the use of human pluripotent stem cell-derived cardiomyocytes (iPSC-CM) to generate pulsatile conduits capable of growing and developing over time within the recipient. However, current strategies for rapidly fabricating large-scale engineered heart muscle to create such conduits face limitations, including the shear stress generated during most bioprinting processes along with harsh enzymatic treatments required for initial singularization of cells prior to bioprinting, which together can compromise cell viability and downstream tissue function. Here, we explored the use of derived cardiovascular progenitors (iPSC-CVP) as an alternative to fully differentiated cardiomyocytes as a potential cell source for future biomanufacturing efforts. We demonstrate that iPSC-CVP can be used to form functional engineered heart tissues with similar electrophysiological properties to tissues formed from fully differentiated iPSC-CM, while also being more amenable to enzymatic dissociation and mechanical manipulation. Our results suggest that iPSC-CVP may be an ideal cell population for future efforts in biofabrication of contractile structures such as engineered heart muscle and pulsatile conduits.
- 20 January 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2202275
Live Cell Lineage Tracing of Dormant Cancer Cells
Breast cancer is a leading cause of global cancer‐related deaths, and metastasis is the overwhelming culprit of poor patient prognosis. The most nefarious aspect of metastasis is dormancy, a prolonged period between primary tumor resection and relapse. Current therapies are insufficient at killing dormant cells; thus, they can remain quiescent in the body for decades until eventually undergoing a phenotypic switch, resulting in metastases that are more adaptable and drug resistant. Unfortunately, dormancy has few in vitro models, largely because lab‐derived cell lines are highly proliferative. Existing models address tumor dormancy, not cellular dormancy, because tracking individual cells is technically challenging. To combat this problem, a live cell lineage approach to find and track individual dormant cells, distinguishing them from proliferative and dying cells over multiple days, is adapted. This approach is applied across a range of different in vitro microenvironments. This approach reveals that the proportion of cells that exhibit long‐term quiescence is regulated by both cell intrinsic and extrinsic factors, with the most dormant cells found in 3D collagen gels. This paper envisions that this approach will prove useful to biologists and bioengineers in the dormancy community to identify, quantify, and study dormant tumor cells.
- 20 January 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2202275
Live Cell Lineage Tracing of Dormant Cancer Cells
Breast cancer is a leading cause of global cancer‐related deaths, and metastasis is the overwhelming culprit of poor patient prognosis. The most nefarious aspect of metastasis is dormancy, a prolonged period between primary tumor resection and relapse. Current therapies are insufficient at killing dormant cells; thus, they can remain quiescent in the body for decades until eventually undergoing a phenotypic switch, resulting in metastases that are more adaptable and drug resistant. Unfortunately, dormancy has few in vitro models, largely because lab‐derived cell lines are highly proliferative. Existing models address tumor dormancy, not cellular dormancy, because tracking individual cells is technically challenging. To combat this problem, a live cell lineage approach to find and track individual dormant cells, distinguishing them from proliferative and dying cells over multiple days, is adapted. This approach is applied across a range of different in vitro microenvironments. This approach reveals that the proportion of cells that exhibit long‐term quiescence is regulated by both cell intrinsic and extrinsic factors, with the most dormant cells found in 3D collagen gels. This paper envisions that this approach will prove useful to biologists and bioengineers in the dormancy community to identify, quantify, and study dormant tumor cells.